Answer
Posterior reversible encephalopathy syndrome reported during ponatinib treatment can cause seizures, headache, decreased alertness, altered mental functioning, vision loss, and other visual and neurological disturbances.
Sources for this answer
- Ponatinib Incyte 30 mg film-coated tabletsIncyte Biosciences UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 3Document updated
Sources checked